The UK and US have agreed to a key commercial pact that will keep zero duties on UK medicine shipments entering the US market.
Key Provisions of the Accord
In exchange for the tariff guarantee, the UK has agreed to raise funding on drugs through the NHS. This commitment secures that import taxes on these crucial products will be held at zero for a period of three years.
This deal follows recent warnings to significantly raise import taxes on branded drug imports, with increases floated as high as double the cost.
"This deal with the United Kingdom reinforces the global environment for cutting-edge drugs and establishes much-needed equity to U.S.–U.K. drug exports," a statement said.
Economic Importance
Drugs are one of the UK's biggest export categories to the US, which is by far the largest market for major UK drugmakers.
Trade data reveal that in the 12 months to the end of the third quarter, the UK shipped drugs totaling billions to the US. This figure represented nearly one-fifth of total UK exports in that timeframe.
"This deal safeguards jobs, boosts funding and facilitates the UK to become a international leader for biotech and pharma," a minister commented.
Key NHS Changes
The deal includes several key pledges from the United Kingdom:
- Revised Affordability Limit: The UK will lift the price threshold at which it deems new treatments to be prohibitively costly by twenty-five percent.
- Higher Drug Budget: There is a target to double total health service expenditure on drugs from 0.3 percent of the national economy to 0.6 percent over the following ten-year period.
- Rebate Cap: The amount manufacturers must pay back to the NHS to prevent overspending will be capped at fifteen percent. Previously, rebates topped twenty percent.
Industry Background
This agreement takes place against a ongoing row between the pharmaceutical industry and the ministers over spending levels and approval rates.
The disagreement were intensified by assertions that American patients were paying a premium for the same drugs than consumers in the Britain and the EU.
In recent months, several major manufacturing plans in the UK have been halted or abandoned, while major funding commitments have been announced toward American operations.
One official acknowledged that the NHS needed to increase expenditure on medicines, noting that its spending on drugs had decreased as a proportion of its total funding over the past decade.
